Showing results (541-550 of 1,014) with videos related to

Sort By:
Pageof 102
Clinical Journal of the American Society of Nephrology : CJASN|March 21, 2019
Rates of Cardiac Rhythm Abnormalities in Patients with CKD and DiabetesNazem Akoum, Leila R Zelnick, Ian H de Boer, et al.
Diabetes Technology & Therapeutics|August 14, 2008
Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM)Irl B Hirsch, Dana Armstrong, Richard M Bergenstal, et al.
British Journal of Cancer|September 5, 2013
Exogenous hormone use, reproductive history and risk of adult myeloid leukaemiaJ N Poynter, R Fonstad, C K Blair, et al.
Diagnostic Immunology|January 1, 1985
Comparison of detection of oligoclonal immunoglobulin G bands in cerebrospinal fluid specimens by Coomassie blue and silver stainsA B Chu, L Nerurkar, D Arthur, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|October 22, 2015
Biscationic Tartaric Acid-Based Amphiphiles: Charge Location Impacts Antimicrobial ActivityAllison Faig, Timothy D Arthur, Patrick O Fitzgerald, et al.
Veterinary Pathology|December 23, 2023
Epizootic of enterocolitis and clostridial overgrowth in NSG and NSG-related mouse strainsJustin D Arthur, Jeannie L Mullen, Francisco A Uzal, et al.
Leukemia|September 26, 1997
Cytogenetically aberrant cells are present in the CD34+CD33-38-19- marrow compartment in children with acute lymphoblastic leukemiaC A Quijano, D Moore, D Arthur, et al.
Annals of Surgery|August 19, 2014
Perioperative hyperglycemia and risk of adverse events among patients with and without diabetesMeera Kotagal, Rebecca G Symons, Irl B Hirsch, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1982
Parkinson's disease: Cogentin with Sinemet, a better responseW W Tourtellotte, A R Potvin, K Syndulko, et al.
Diabetes Care|August 31, 2012
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trialIrl B Hirsch, Bruce Bode, Jean-Pierre Courreges, et al.
Pageof 102